Enovis (NYSE:ENOV) Insider Oliver Engert Purchases 1,200 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were acquired at an average price of $23.00 per share, for a total transaction of $23,000.00.
• On Monday, June 1st, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were acquired at an average price of $22.22 per share, for a total transaction of $22,220.00.

Enovis Price Performance

NYSE ENOV opened at $20.91 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The firm’s 50 day moving average price is $24.00 and its 200-day moving average price is $24.50. Enovis Corporation has a 52-week low of $20.55 and a 52-week high of $36.82. The company has a market cap of $1.20 billion, a PE ratio of -1.05 and a beta of 1.38.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same period last year, the firm earned $0.81 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts forecast that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Enovis

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its stake in Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after acquiring an additional 621 shares in the last quarter. MGO One Seven LLC lifted its stake in shares of Enovis by 9.4% during the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after buying an additional 650 shares during the period. Rhumbline Advisers lifted its stake in shares of Enovis by 0.4% during the third quarter. Rhumbline Advisers now owns 173,023 shares of the company’s stock worth $5,250,000 after buying an additional 682 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. Finally, Empowered Funds LLC lifted its stake in shares of Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Evercore reiterated an “outperform” rating and set a $36.00 price objective on shares of Enovis in a research note on Friday, May 8th. Needham & Company LLC raised their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Wells Fargo & Company lowered their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.